Search company, investor...

Predict your next investment

Novo Nordisk company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
novonordisk.com

Investments

27

Portfolio Exits

10

Partners & Customers

10

Service Providers

1

About Novo Nordisk

Novo Nordisk (CPH: NOVO-B) is a healthcare company that specializes in diabetes care. It also operates in hemophilia care, growth hormone therapy and hormone replacement therapy. The company was founded in 1989 and is based in Bagsvaerd, Denmark.

Headquarters Location

Novo Alle

Bagsvaerd, 2880,

Denmark

+45 4444 8888

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Expert Collections containing Novo Nordisk

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Novo Nordisk in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

C

Conference Exhibitors

5,302 items

Latest Novo Nordisk News

Chasing Weight Loss Dream, Many In US Seek Ozempic Alternatives

Dec 4, 2023

In addition to the millions of diabetic and obese patients seeking out drugs like Ozempic, countless others without severe health issues are asking doctors for 'off-label' prescriptions, leading to a major supply crunchAFP Like many Americans struggling to lose weight, Marissa Montanino felt compelled to try Ozempic or one of the other new so-called "wonder drugs" described as revolutionary in the fight against obesity. "I would work out sometimes three times a day, I was doing hours worth of classes. I was eating really, really clean... and nothing was changing" the 36-year-old esthetician told AFP in a recent interview. "I heard about Ozempic for a while and then you start to see other people doing it like celebrities and then dropping weight super fast," she said. Fearing gastrointestinal issues, a side effect of the drugs, Montanino sought reassurance from clients at her studio and in Facebook support groups. "I was scared. I was super nervous. I am terrified of being nauseous," she said. Ultimately deciding to take the leap, Montanino was not prescribed Ozempic, made by Danish drugmaker Novo Nordisk, but rather "compounded" semaglutide. It's an option many in the United States are turning to over cost or supply problems with the brand name drugs -- but which experts and officials have flagged for possible risks. Over 40 percent of Americans suffer from obesity, reflecting a major health crisis and the massive market for new Ozempic-type drugs. With their "groundbreaking" effectiveness, the drugs will be "the first line therapy for people who are obese," research physician Samuel Klein of Washington University in St. Louis told AFP. Semaglutide is the active ingredient in both Ozempic -- approved as a diabetes treatment in 2017 -- and Novo Nordisk's Wegovy, which gained authorization as an obesity medicine in 2021. In addition to the millions of diabetic and obese patients seeking out the drugs, countless others without severe health issues are asking doctors for "off-label" prescriptions. Celebrities, including Elon Musk, have also said they take the drugs to shed pounds -- fueling skyrocketing interest. "The major problem is that it is now difficult to get the medications," said Klein. "There's not enough medication being made." The US Food and Drug Administration (FDA) classifies semaglutide and tirzepatide -- the compound used by Eli Lilly in its drugs Mounjaro and Zepbound -- as currently "in shortage." The designation means some restrictions may be lifted, allowing the compounding of drugs that are "essentially copies of approved drugs," the FDA says. Compounding, the creation of custom drugs, has historically been used when a patient has an allergy to a medicine's component. Obesity specialist Andrea Coviello told AFP she is concerned about patients taking compounded weight loss drugs, often ordered online. Though some of her patients who say they've tried the compounded drugs lost weight, it's "unclear what these patients are actually receiving," the UNC School of Medicine professor and physician said. Montanino, who is just over five feet (1.53 meters) tall, says that in less than six months using the weekly injections, she has gone down from 157 pounds (71.2 kilograms) to around 130. Her target is 125. She said that in her group chat with others taking weight loss drugs, only one was on brand name Wegovy, and that "everybody's super happy." US authorities warn that "compounded drugs pose a higher risk to patients than FDA-approved drugs" because they "do not undergo FDA premarket review for safety, effectiveness, or quality." Without further details, it says it has "received adverse event reports after patients used compounded semaglutide." An online search for compounded weight loss drugs produces handfuls of retailers offering to ship the medicine by mail. Advertised prices are much lower than the brand name sticker price, but not necessarily cheaper than when insurance covers it. Montanino said she initially paid $300 for a three-month supply, but as the dosage increases over time it could eventually become $300 per month. Given the booming demand for the drugs, it is unclear when they may come off the shortage list. Already earning billions each quarter on their branded weight-loss medications, Novo Nordisk and Eli Lilly stand to gain even more if they can remove the "shortage" designation, and are ramping up production. Both have also filed multiple suits against compounding pharmacies, which are making their way through court. Despite the uncertainty, Montanino said she intends to keep using the drugs, "for life" if possible. She and her husband, whom she says also lost 50 pounds, celebrated their weight loss by retaking wedding photos on their one-year anniversary. "I'm happier in my skin. I'm happier with how clothes fit. I hate saying that... But for me, it makes me feel better." Semaglutide is the active ingredient in both Ozempic -- approved as a diabetes treatment in 2017 -- and Novo Nordisk's Wegovy, which gained authorization as an obesity medicine in 2021AFP Propelled by growing sales of Ozempic, Denmark-based Novo Nordisk has become Europe's most valuable company and is seeking to rapidly expand its production capacityAFP © Copyright AFP 2023. All rights reserved. IBT Fast Start - Let the best of International News come to you Sign up and stay up to date with our daily newsletter. You can unsubscribe at any time. By signing up you are agreeing to our Terms of Service and Privacy Policy . Join the Discussion

Novo Nordisk Investments

27 Investments

Novo Nordisk has made 27 investments. Their latest investment was in ElevateBio as part of their Series D on May 5, 2023.

CBI Logo

Novo Nordisk Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/24/2023

Series D

ElevateBio

$401M

Yes

10

4/12/2023

Convertible Note

Aspect Biosystems

$55.75M

Yes

2

12/19/2022

Series B

Amalgam Rx

$17.37M

Yes

2

2/18/2022

Series C

Subscribe to see more

$99M

Subscribe to see more

10

3/16/2021

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/24/2023

4/12/2023

12/19/2022

2/18/2022

3/16/2021

Round

Series D

Convertible Note

Series B

Series C

Series D

Company

ElevateBio

Aspect Biosystems

Amalgam Rx

Subscribe to see more

Subscribe to see more

Amount

$401M

$55.75M

$17.37M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

10

2

2

10

10

Novo Nordisk Portfolio Exits

10 Portfolio Exits

Novo Nordisk has 10 portfolio exits. Their latest portfolio exit was Disc Medicine on December 29, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/29/2022

Reverse Merger

$99M

5

7/17/2020

IPO

$99M

Public

3

8/1/2019

IPO

$99M

Public

3

5/26/2016

IPO

Subscribe to see more

$99M

Subscribe to see more

10

12/18/2014

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/29/2022

7/17/2020

8/1/2019

5/26/2016

12/18/2014

Exit

Reverse Merger

IPO

IPO

IPO

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

5

3

3

10

10

Novo Nordisk Acquisitions

15 Acquisitions

Novo Nordisk acquired 15 companies. Their latest acquisition was Embark Biotech on August 30, 2023.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/30/2023

$99M

Acquired

3

8/10/2023

Series C

$99M

$109.4M

Acquired

4

8/4/2023

$99M

Corporate Majority - P2P

3

9/1/2022

Series D

Subscribe to see more

$99M

$99M

Subscribe to see more

10

12/28/2021

Series C

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

8/30/2023

8/10/2023

8/4/2023

9/1/2022

12/28/2021

Investment Stage

Series C

Series D

Series C

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$109.4M

$99M

$99M

Note

Acquired

Acquired

Corporate Majority - P2P

Subscribe to see more

Subscribe to see more

Sources

3

4

3

10

10

Novo Nordisk Partners & Customers

10 Partners and customers

Novo Nordisk has 10 strategic partners and customers. Novo Nordisk recently partnered with Genevant on November 11, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

11/6/2023

Partner

United States

1

10/19/2023

Partner

United States

GE HealthCare and Novo Nordisk to Collaborate to Advance Novel Non-Invasive Treatment for Type 2 Diabetes and Obesity with Ultrasound

GE HealthCare Technologies Inc. today announced a collaboration with Novo Nordisk to further advance the clinical and product development of peripheral focused ultrasound .

5

10/18/2023

Partner

United States, United Kingdom, and Switzerland

Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

18 , 2023 -- Meharry Medical College , along with partners Regeneron ® , AstraZeneca , Novo Nordisk , and Roche , today announced the launch of the Together for CHANGE ™ initiative to create better health care and outcomes for all .

2

9/25/2023

Partner

United States

Subscribe to see more

Subscribe to see more

10

9/20/2023

Vendor

Switzerland

Subscribe to see more

Subscribe to see more

10

Date

11/6/2023

10/19/2023

10/18/2023

9/25/2023

9/20/2023

Type

Partner

Partner

Partner

Partner

Vendor

Business Partner

Country

United States

United States

United States, United Kingdom, and Switzerland

United States

Switzerland

News Snippet

GE HealthCare and Novo Nordisk to Collaborate to Advance Novel Non-Invasive Treatment for Type 2 Diabetes and Obesity with Ultrasound

GE HealthCare Technologies Inc. today announced a collaboration with Novo Nordisk to further advance the clinical and product development of peripheral focused ultrasound .

Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

18 , 2023 -- Meharry Medical College , along with partners Regeneron ® , AstraZeneca , Novo Nordisk , and Roche , today announced the launch of the Together for CHANGE ™ initiative to create better health care and outcomes for all .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

5

2

10

10

Novo Nordisk Service Providers

1 Service Provider

Novo Nordisk has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Merger

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Merger

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Novo Nordisk Team

42 Team Members

Novo Nordisk has 42 team members, including current Chief Executive Officer, President, Lars Fruergaard Jørgensen.

Name

Work History

Title

Status

Lars Fruergaard Jørgensen

Chief Executive Officer, President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Lars Fruergaard Jørgensen

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer, President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Novo Nordisk to Competitors

B
BMS

BMS focuses on strategic, pioneering, and original research and development in the field of international blood technology. The company was founded in 2004 and is based in Wuhan, China.

V
ViCardia Therapeutics

ViCardia Therapeutics is a clinical-stage biopharmaceutical company. The company focuses on the discovery, development, and commercialization of therapies for treating heart failure involving mitochondrial dysfunction. It was founded in 2017 and is based in San Francisco, California.

Novartis Logo
Novartis

Novartis (NYSE: NVS) researches, develops, manufactures, and markets healthcare products. It provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The company was founded in 1996 and is based in Basel, Switzerland.

Cytokinetics Logo
Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company that operates in the healthcare sector, with a focus on muscle biology and the mechanics of muscle performance. The company's main offerings include the development of small molecule drug candidates specifically engineered to impact muscle function and contractility, aiming to treat debilitating diseases where muscle performance is compromised or declining. Cytokinetics primarily serves the healthcare industry, particularly in areas related to cardiovascular and neuromuscular muscle dysfunction. It was founded in 1997 and is based in South San Francisco, California.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.